Dr Adam ChambersPrincipal Scientist
Adam completed his BSc in Biotechnology at Oxford Brookes University. His third year was spent working on placement with Professor Possee at the Centre of Ecology and Hydrology (CEH) in Oxford on insect baculovirus molecular biology. After the final year of his degree he embarked upon a PhD at Oxford Brookes University with Professor Linda King. His research project concerned the role of ODV structural proteins in baculovirus replication. Following his PhD, Adam joined OET in 2010 as a junior scientist but is now one of the senior scientists within the company and oversees the successful running of the laboratory facilities and its research staff.
Dr Mine AksularSenior Scientific Officer
Mine completed her BSc in Biomedical Sciences at Oxford Brookes University where she first gained an interest in baculovirus research whilst carrying out her undergraduate project with Prof Linda King. She then moved to London to study for her MSc in Infection and Immunity at the University College London before securing a PhD position as part of a collaboration between Oxford Brookes University, the BBSRC Pirbright Institute and OET. This project concerned investigating the antigenic structure of African horse sickness virus (AHSV) VP2 protein which provides the groundwork for generating baculovirus-based AHSV vaccines. Mine came to work for OET in 2016 and carries out essential research in the production of a vaccine towards CCHF virus and also the development of gene therapies against type I diabetes.
Dr Leo GravesSenior Scientific Officer
Leo received his BSc in Biotechnology at Oxford Brookes University, which included a year’s placement working at the Centre of Ecology and Hydrology (CEH). After this he started work at Allergy Therapeutics as part of the quality control and research & development division. He was then accepted for a funded PhD position at Oxford Brookes University to work with Prof Linda King on understanding the functional role of a highly expressed baculovirus protein, P10. Shortly afterwards Leo joined OET part-time in 2017 before moving to full-time employment in early 2018. He previously worked with OET’s UK-Mexico collaboration (TRANSDIA) to investigate the use of baculovirus in the development of gene therapies for diabetes type I and is currently working on the company services.
Cassandra RigbyHigher Scientific Officer
Cassandra finished her BSc in Pharmacology at King’s College London. The duration of her third year was spent completing an industrial placement at MRC Technology (now LifeArc) working on developing small molecule inhibitors against a metabolic target for the treatment of metastatic breast cancer. After leaving university she worked for 6 months at QuintilesIMS (now IQVIA) as a clinical trial research assistant where she gained experience in Phase I-III clinical trials. Cassandra joined OET in early 2018 to provide research assistance for the second stage of the CCHF vaccine project.
Dr Stephen AdeniyiSenior Scientific Officer
Stephen attained his BSc (Hons) in Biochemistry at Ajayi Crowther University. He subsequently decided to further his studies by undertaking MSc in Biotechnology at the University of Bedfordshire, which saw him receiving a most meritorious postgraduate award for his achievement in Biotechnology. He relocated to Scotland and was granted a scholarship for a PhD opportunity at University of Aberdeen. His doctoral research focused on the regulation of ribosome biosynthesis by cell physiology in budding yeast. Upon the completion of his PhD, Stephen moved back to England for postdoctoral research to isolate and purify ribosomes in bacteria at the Queen Mary University of London. Shortly after, Stephen joined OET in the summer of 2022. He currently works on the company’s service projects using baculovirus-insect expression and protein purification.
Durva SevakScientific Officer Kits & Products
Durva completed a degree in Biomedical Science at Oxford Brookes University before undertaking an MRes degree in Cancer Sciences at Birmingham University. Her area of research concerned a novel gene with a potential role in the Fanconi Anaemia tumour suppressor pathway. After finishing her studies, Durva joined OET in 2016 to work exclusively on the applications of baculovirus technology in the production of a viable vaccine for CCHF virus. Her involvement with the project from the outset has provided extensive experience and knowledge which will be beneficial as she continues to provide support during the next stage of its development.
Adina HupiScientific Officer
Adina completed a European Baccalaureate in Romania and a degree in Biomedical Science at Oxford Brookes University. She also worked with the African Swine Fever Vaccine Group at the Pirbright Institute for 6 months during her placement year. Her area of research involved looking at antibodies using optimized ELISA and on other projects too. She has experience in cell culture and microscopy. After finishing her studies, Adina joined OET to work on our ongoing projects like vaccine development and protein expression.
Georgia WoodScientific Officer
Georgia completed a degree in Biological Sciences at Oxford Brookes University and wrote a bioinformatics-based dissertation where she discovered a novel gene in Lepidoptera which plays a large role in the immune response during its embryo stage. She has recently joined OET as a Scientific Officer and is helping with ongoing projects like vaccine development and protein expression as well as with administration in the lab from maintenance to purchasing.